157 related articles for article (PubMed ID: 21304505)
1. Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?
Gómez-Puerta JA; Bosch X
Nat Rev Rheumatol; 2011 Mar; 7(3):134-6. PubMed ID: 21304505
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Okamoto H; Kobayashi A
N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
[No Abstract] [Full Text] [Related]
3. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Otón T; Silva-Fernández L; Andreu JL
N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
[No Abstract] [Full Text] [Related]
4. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
5. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
6. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Boers M
Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
[No Abstract] [Full Text] [Related]
7. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
[TBL] [Abstract][Full Text] [Related]
8. Healing the Syk through kinase inhibitors.
Rivera J; Colbert RA
N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
[No Abstract] [Full Text] [Related]
9. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
Nijjar JS; Tindell A; McInnes IB; Siebert S
Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
[TBL] [Abstract][Full Text] [Related]
11. American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al.
Felson DT
Arthritis Rheum; 2011 Oct; 63(10):3181-2; author reply 3182. PubMed ID: 21769845
[No Abstract] [Full Text] [Related]
12. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
13. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
Bajpai M; Chopra P; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2008 May; 17(5):641-59. PubMed ID: 18447591
[TBL] [Abstract][Full Text] [Related]
16. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
17. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Scott IC; Scott DL
Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis in 2010: from the gut to the joint.
Scheinecker C; Smolen JS
Nat Rev Rheumatol; 2011 Feb; 7(2):73-5. PubMed ID: 21289609
[No Abstract] [Full Text] [Related]
19. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Baluom M; Samara E; Grossbard EB; Lau DT
J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
